DexCom earnings beat by $0.03, revenue topped estimates
In a recent filing with the Securities and Exchange Commission, Saba Capital Management, L.P. reported the sale of 48,623 shares of abrdn Life Sciences Investors (NYSE:HQL) common stock. The shares were sold at a price of $12.58 each, resulting in a total transaction value of approximately $611,677. The stock currently trades at $12.34, near its 52-week low of $12.37, while offering an attractive dividend yield of ~15%. Following this transaction, Saba Capital Management holds 3,188,405 shares of abrdn Life Sciences Investors, representing a significant position in the $345M market cap company. The filing, dated March 31, 2025, lists Boaz Weinstein as a reporting owner, alongside Saba Capital Management. InvestingPro analysis reveals the fund has maintained dividend payments for 30 consecutive years, with additional financial health metrics and insights available to subscribers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.